Perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer
Year: 2026
Type: article
Abstract: T he combination of perioperative apalutamide with androgen deprivation therapy (ADT) significantly improved pathologic complete response (pCR)/minimal residual disease (MRD) and metastasis-free survival (MFS) in patients with high-risk localized or locally advanced prostate cancer according to results of the PROTEUS trial.Mary-Ellen Taplin, MD, a professor of medicine at Harvard Medical School in Boston, Massachusetts, presented the results of PROTEUS at the
Source: Cancer
DOI: 10.1002/cncr.70637
Author: Leah Lawrence
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7227128642
